Ethicon Endo-Surgery, Inc. v. Covidien, Inc.

796 F.3d 1312, 115 U.S.P.Q. 2d (BNA) 1880, 2015 U.S. App. LEXIS 13798, 2015 WL 4680726
CourtCourt of Appeals for the Federal Circuit
DecidedAugust 7, 2015
Docket2014-1370
StatusPublished
Cited by128 cases

This text of 796 F.3d 1312 (Ethicon Endo-Surgery, Inc. v. Covidien, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ethicon Endo-Surgery, Inc. v. Covidien, Inc., 796 F.3d 1312, 115 U.S.P.Q. 2d (BNA) 1880, 2015 U.S. App. LEXIS 13798, 2015 WL 4680726 (Fed. Cir. 2015).

Opinion

CHEN, Circuit Judge.

Plaintiffs-appellants Ethicon Endo-Sur-gery, Inc. and Ethicon Endo-Surgery, LLC (collectively, Ethicon) sued defendants-appellees Covidien, Inc. and Covi-dien LP (collectively, Covidien) in the U.S. District Court for the Southern District of Ohio for alleged infringement of several utility and design patents related to ultrasonic surgical devices. After the close of discovery, the district court granted Covi-dien’s motions for summary judgment, concluding that 1) U.S. Patent No. 8,182,-501 (the '501 patent) is invalid as indefinite, 2) U.S. Patent No. 5,989,275 (the '275 patent) is not infringed by Covidien’s accused products, and 3) U.S. Patent Nos. D661,801 (the D'801 patent), D661,802 (the D'802 patent), D661,803 (the D'803 patent), and D661,804 (the D'804 patent) (collectively, the Design Patents) are invalid as functional and in the alternative, not infringed. The district court entered final judgment in favor of Covidien, and Ethicon now appeals.

We reverse and vacate in part. As to the '501 patent, we reverse the district *1315 court’s grant of invalidity for indefiniteness, because the specification provides sufficient guidance to a person of ordinary skill in the art as to the scope of its asserted claims. As to the '275 patent, we vacate the district court’s grant of summary judgment of noninfringement because the district court improperly resolved genuine disputes of material fact in favor of Covidien instead of Ethicon, the non-moving party, and questions of fact remain as to whether Covidien’s accused ultrasonic devices infringe the asserted claims of the '275 patent.

As for the Design Patents, we reverse the district court’s grant of invalidity based on functionality. The district court evaluated the claimed designs using too high a level of abstraction, focusing on the unclaimed utilitarian aspects of the underlying article instead of the claimed ornamental designs of that underlying article. We affirm, however, the district court’s grant of summary judgment of nonin-fringement of the Design Patents. After the functional aspects of the claimed designs are properly excluded from the infringement analysis, the claimed ornamental designs are plainly dissimilar from the ornamental design of Covidien’s accused products. Based on the foregoing, we remand to the district court to resolve Ethi-con’s allegations that Covidien’s accused devices infringe the asserted claims of the '501 and '275 patents.

I. Background

The patents-in-suit are directed to surgical instruments that use ultrasonic energy created by blades vibrating at high frequencies to cut tissue and blood vessels. These surgical instruments also use the heat generated from the friction of the blade vibrating against the blood vessel to coagulate and seal those blood vessels in order to prevent bleeding. Ethicon develops, manufactures, and sells such ultrasonic surgical instruments. After Covidien launched a competing line of ultrasonic surgical equipment, Ethicon sued Covi-dien, alleging infringement of the utility and design patents at issue in this appeal, among others. Both parties waived their rights to a jury trial and agreed to a bench trial on all disputed issues. After Markman proceedings and the close of discovery, Covidien successfully moved for summary judgment of invalidity and/or noninfringement of the asserted patent claims. See Ethicon Endo-Surgery, Inc. v. Covidien, Inc., No. 11-cv-871, ECF Nos. 130-32 (S.D. Oh. Jan. 22, 2014) (Ethi-con DCt). The district court entered a stipulated final judgment of noninfringement and/or invalidity of all patents-in-suit in favor of Covidien. Ethicon timely appealed, and we have jurisdiction over Ethi-con’s appeal pursuant to 28 U.S.C. § 1295(a)(1).

II. Discussion

We review the grant of summary judgment under the law of the regional circuit. Lexion Med., LLC v. Northgate Techs., Inc., 641 F.3d 1352, 1358 (Fed.Cir.2011). The Sixth Circuit reviews an order granting summary judgment de novo. Savage v. Gee, 665 F.3d 732, 737 (6th Cir.2012).

A. The '501 patent

The '501 patent is directed to ultrasonic surgical shears for cutting and sealing a blood vessel. '501 patent, 1:20-23. The claimed device includes an ultrasonic surgical blade, a clamping arm, and a tissue pad attached to the clamping arm. Id. at 2:7-10. The clamping arm opens and closes towards the ultrasonic blade in a *1316 manner similar to the two blades of a pair of scissors. Id. at 2:8-9. During use, a blood vessel is positioned between the blade and the tissue pad on the clamping arm. Id. at 1:67-2:2. When the blade and clamping arm are in a “closed position,” the average clamping pressure on the blood vessel is between 60 and 210 pounds per square inch (psi). Id. at 2:2-4. The ultrasonic blade then vibrates at a high frequency. Id. at 2:4-5. The combination of this ultrasonically-vibrating blade and clamping pressure on the blood vessel results in the bringing together the walls of the blood vessel (a “coaptation”), the cutting of the coaptated blood vessel (a “tran-section”), and the sealing of the coaptated cut ends of the blood vessel (a “coagulation”). Id. at 1:40-46. According to the '501 patent, the 60 to 210 psi average clamping pressure range provides improved blood vessel sealing with shorter transection times on smaller blood vessels and blood vessel sealing with acceptable transection times on larger blood vessels, a result which was not conventionally achievable. Id. at 2:25-31. Claim 17 is representative, and recites as follows:

17. An ultrasonic surgical shears comprising:
a) an ultrasonic surgical blade;
b) a clamping arm operable to open and close toward the blade;
c) a tissue pad attached to the clamping arm, wherein the blade and tissue pad define a clamping surface area so that the applied clapip force does not exceed a clamping pressure of 210 psi at the clamping surface area; and
d) means for limiting a user applied clamping force on the clamping arm creating an average predetermined clamping pressure between and including 60 psi and 210 psi on tissue disposed between the tissue pad and the blade.

Id. at 7:15-27 (emphases added).

Each asserted claim of the '501 patent includes at least one limitation that requires clamping pressure values similar to those recited in claim 17. Ethicon DCt, ECF No. 131 at 49. The asserted claims recite either an “average” clamping/coap-tation pressure (e.g., claims 1 and 17) or simply a “clamping pressure” (e.g., claims 12, 22, and 23). We understand the '501 patent’s specification to use “clamping pressure” interchangeably with “average” clamping/coaptation pressure.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Terracino v. Trimaco, Inc.
E.D. North Carolina, 2024
JACKI EASLICK, LLC v. CJ EMERALD
W.D. Pennsylvania, 2024

Cite This Page — Counsel Stack

Bluebook (online)
796 F.3d 1312, 115 U.S.P.Q. 2d (BNA) 1880, 2015 U.S. App. LEXIS 13798, 2015 WL 4680726, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ethicon-endo-surgery-inc-v-covidien-inc-cafc-2015.